$1.6M
+$1.6M this year1 filing since 2026 · latest Debt filed
PanGIA Biotech is a Delray Beach, Florida biotechnology company developing non-invasive liquid biopsy tests for early cancer detection. Its PanGIA Analysis System profiles biomolecular signatures in urine and cerebrospinal fluid and applies machine learning pattern recognition to detect cancer as early as Stage 1. Its lead product, the PanGIA Prostate assay, is an AI-integrated urine-based liquid biopsy for prostate cancer; a peer-reviewed study in Diagnostics reported 97.8% sensitivity, and the company announced a partnership to commercially launch the assay in India. Assays for roughly ten additional cancers, including lung, pancreatic, ovarian and breast, are in its R&D pipeline.
What sets it apart
A urine-based liquid biopsy that reads whole biomolecular-signature patterns with machine learning rather than a single biomarker, avoiding blood draws and biopsies while remaining cheap enough to scale globally.
An AI-integrated, urine-based liquid biopsy test for detecting clinically significant prostate cancer, replacing blood draws and invasive tissue biopsies with a simple urine sample.
